Glial Cell Reprogramming via Microfluidic Constriction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing glial cells, such as oligodendrocyte progenitor cells, are inefficient, time-consuming, and often result in heterogeneous cell populations with low frequency of desired cells, posing challenges for regenerative medicine, especially for treating demyelinating diseases.
Innovation Solution
A method involving passing a cell suspension through a constriction under specific parameters to deform cells and create perturbations in the cell membrane, allowing glial cell reprogramming factors to enter and reprogram the cells into glial cells, such as oligodendrocyte progenitor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If iPSC differentiation methods are used to produce glial cells, then various cell types can be generated, but the process takes several weeks to months and results in heterogeneous cell populations with low frequency of desired cells
Solution Approach 1:
The patent applies preliminary action by pre-loading reprogramming factors into cells before differentiation. The cell population is contacted with reprogramming factors in advance, and then subjected to constriction treatment that facilitates factor entry. This preliminary preparation accelerates the differentiation process and increases the frequency of desired glial cells, resolving the contradiction between production efficiency and time consumption.
2Productivity
If lentiviral vectors are used for somatic cell transdifferentiation, then reprogramming can be achieved, but there is a risk of insertional mutagenesis
Solution Approach 1:
The patent extracts the reprogramming function from viral vectors and implements it through a physical constriction mechanism. Instead of using lentiviral vectors that carry reprogramming genes and risk insertional mutagenesis, the patent uses a constriction device that physically facilitates the entry of reprogramming factors into cells. This separates the delivery mechanism from the genetic material, eliminating the safety risk while maintaining reprogramming efficiency.
3Productivity
If electroporation or lipofection methods are used for cell reprogramming, then gene delivery can be achieved, but cell health is negatively affected and cytotoxicity issues arise
Solution Approach 1:
The patent replaces the chemical/electrical mechanical systems of electroporation and lipofection with a purely mechanical constriction-based system. Instead of using electric fields or chemical lipids that cause cellular stress and cytotoxicity, the patent uses a physical constriction mechanism that gently facilitates factor entry. This mechanical substitution maintains gene delivery efficiency while preserving cell health and viability, resolving the contradiction between productivity and reliability.
4Adaptability or versatility
If current methods are used to produce glial cells, then cell replacement therapy can be attempted, but the resulting heterogeneous population reduces therapeutic effectiveness
Solution Approach 1:
The patent applies local quality by creating a specific localized environment during constriction where reprogramming factors are concentrated and efficiently delivered. The constriction mechanism creates a localized zone of enhanced factor entry, ensuring that each cell receives the appropriate reprogramming signal. This localized approach ensures homogeneous cell population with high frequency of desired glial cells, improving manufacturing precision while maintaining therapeutic adaptability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the efficient and cost-effective production of consistent glial cell populations, potentially improving therapeutic applications in regenerative medicine for demyelinating diseases by facilitating remyelination.
Implementation Method 1
passing the cell suspension through the constriction under one or more parameters deforms one or more cells of the population of cells
Implementation Method 2
deforms one or more cells of the population of cells, and thereby, causing a perturbation in the cell membrane
Data Source
AI summary
The present disclosure provides methods for reprogramming a cell into a glial cell (e.g., an oligodendrocyte progenitor cell), wherein the method comprises passing a cell suspension comprising the cell and a glial cell reprogramming factor through a constriction, wherein the constriction deforms the cell, thereby causing a perturbation of the cell such that the glial cell reprogramming factor enters the cell.